<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02740270</url>
  </required_header>
  <id_info>
    <org_study_id>CGWN323X2101</org_study_id>
    <secondary_id>2015-004206-42</secondary_id>
    <nct_id>NCT02740270</nct_id>
  </id_info>
  <brief_title>Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas</brief_title>
  <official_title>A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to explore the clinical utility of two investigational
      antibodies in patients with advanced cancer or lymphomas.

      This is a multi-center, open-label Phase I/Ib study. The study consists of two dose
      escalation parts and two dose expansion parts testing GWN323 as a single agent or GWN323 in
      combination with PDR001. The dose escalation parts will estimate the MTD and/or RDE and test
      different dosing schedules.

      The dose expansion parts of the study will use the MTD/RDE determined in the dose escalation
      part to assess the activity, safety and tolerability of the investigational products in
      patients with specific types of cancer and lymphomas.

      Approximately 264 adult patients with advanced solid tumors or lymphomas will be enrolled.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2016</start_date>
  <completion_date type="Anticipated">December 5, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs) - Single Agent</measure>
    <time_frame>21 days</time_frame>
    <description>Dose Limiting Toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs) - Combination Agents</measure>
    <time_frame>42 days</time_frame>
    <description>Dose Limiting Toxicities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR),</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>per irRC and RECIST v1.1 or Cheson (2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of GWN323 as a single agent: Cmax</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of GWN323 in combination with PDR001 and derived PK parameters: Cmax</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and titer of anti-GWN323 antibodies</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of the effector/regulatory T cell ratio</measure>
    <time_frame>at screening, 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of GWN323 as a single agent: AUC</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of GWN323 in combination with PDR001 and derived PK parameters: AUC</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and titer of anti-PDR001 antibodies</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Lymphomas</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GWN323</intervention_name>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic and/or advanced solid tumors or lymphomas not amenable to
             curative treatment by surgery.

          -  Histologically documented advanced or metastatic solid tumors or lymphomas

          -  Must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy
             according to the treating institution's guidelines. Patient must be willing to undergo
             a new tumor biopsy at screening

          -  ECOG Performance Status â‰¤ 2.

        Exclusion Criteria:

          -  Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases
             that require local CNS-directed therapy (such as radiotherapy or surgery).

          -  Patients diagnosed with T-cell Lymphomas.

          -  Patients with prior allogenic transplants.

          -  Patients previously treated with anti-GITR therapy.

          -  History of severe hypersensitivity reactions to other mAbs.

          -  Patients intolerant to prior immunotherapy (unable to continue/receive due to
             immune-related AE).

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Rainer</last_name>
      <phone>773-702-8582</phone>
      <email>mrainer@bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Luke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natasha Isaac</last_name>
      <phone>617-632-4272</phone>
      <email>Nisaac1@partners.org</email>
    </contact>
    <investigator>
      <last_name>Osama Rahma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepika Cattry</last_name>
      <phone>646-227-2178</phone>
      <email>cattryd@mskcc.org</email>
    </contact>
    <investigator>
      <last_name>Alexander Lesokhin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rabia Khan</last_name>
      <phone>713-563-4667</phone>
      <email>RKhan@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Sarina Piha-Paul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2016</study_first_submitted>
  <study_first_submitted_qc>April 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced solid tumors</keyword>
  <keyword>lymphomas</keyword>
  <keyword>GWN323</keyword>
  <keyword>PDR001</keyword>
  <keyword>advanced malignancies</keyword>
  <keyword>anti-GITR</keyword>
  <keyword>anti-PD-1</keyword>
  <keyword>adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

